{'fraction_non_alphanumeric': 0.014414414414414415, 'fraction_numerical': 0.0, 'mean_word_length': 6.128205128205129, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Updating the relationship between hyperhomocysteinemia lowering therapy and cardiovascular events.

Hyperhomocysteinemia (Hhcy) was defined as an independent risk factor for cardiovascular events. A number of clinical trials had investigated the relationship between Hhcy lowering treatment and cardiovascular diseases, however, the results of these studies remain controversial. This review article gave an over view of the homocysteine metabolisms and updated the recently published results in the role of Hhcy lowering therapy on cardiovascular events.